{"id":"W2946857908","doi":"10.1200/jco.2019.37.15_suppl.tps5604","title":"Phase I (safety assessment) of durvalumab (MEDI4736) with focal sensitizing radiotherapy in platinum resistant ovarian, primary peritoneal or fallopian tube epithelial carcinoma.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Durvalumab; Radioimmunotherapy; Fallopian tube; Tolerability; Response Evaluation Criteria in Solid Tumors; Oncology; Urology; Ovarian carcinoma; Radiation therapy; Internal medicine; Gastroenterology; Ovarian cancer; Chemotherapy; Phases of clinical research; Adverse effect; Immunotherapy; Surgery; Nivolumab; Cancer; Antibody; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001258335,0.001042271,0.001361029,0.0003884416,0.0002674206,0.0008041502,0.0008646865,0.001092141,0.003324472],"category_scores_gemma":[0.0007838727,0.0004487017,0.001040302,0.0004767705,0.0005024691,0.0004952025,0.0003116344,0.00151177,0.0009113516],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001106033,"about_ca_system_score_gemma":0.001281996,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001240246,"about_ca_topic_score_gemma":0.002836855,"domain_scores_codex":[0.9996252,0.0001765526,0.00002214446,0.00006044119,0.00004360446,0.00007197345],"domain_scores_gemma":[0.9995934,0.00005044942,0.0001154561,0.0000572525,0.00002913308,0.0001543636],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.476084,0.06506478,0.01612757,0.002023185,0.002694223,0.0006293973,0.0005665097,0.005585269,0.1305784,0.0005795195,0.006285576,0.2937815],"study_design_scores_gemma":[0.326298,0.6121569,0.03081,0.0001188968,0.001259144,0.001485838,0.0001110589,0.002075069,0.01761856,0.000398483,0.007632489,0.00003553056],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9871925,0.003895679,0.0009974645,0.0003094755,0.00007326165,0.003336552,0.001761116,0.0001290907,0.002304764],"genre_scores_gemma":[0.9840643,0.003572082,0.002423092,0.0007317133,0.00009962187,0.003108078,0.003329905,0.00004077376,0.00263039],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003324472,"threshold_uncertainty_score":0.01112151,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06220732014825342,"score_gpt":0.4392053871118035,"score_spread":0.3769980669635501,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}